Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
| العنوان: | Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials |
|---|---|
| المؤلفون: | Melvin J. Prince, Annette M. Chang, Yongming Qu, Shuyu Zhang, Julio Rosenstock, Edward J. Bastyr, Michel Marre |
| المصدر: | Diabetes, Obesity & Metabolism |
| بيانات النشر: | Blackwell Publishing Ltd, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Blood Glucose, Male, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Insulin Glargine, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, law.invention, Polyethylene Glycols, 0302 clinical medicine, Endocrinology, Randomized controlled trial, law, nocturnal hypoglycaemia, Insulin Lispro, Brief Report, Middle Aged, Themed Section‐bil, Circadian Rhythm, Nocturnal hypoglycaemia, Female, medicine.drug, Adult, medicine.medical_specialty, endocrine system, 030209 endocrinology & metabolism, 03 medical and health sciences, Double-Blind Method, Internal medicine, Internal Medicine, medicine, Humans, Dosing, Aged, Retrospective Studies, Glycated Hemoglobin, Type 1 diabetes, Insulin glargine, business.industry, Basal insulin, nutritional and metabolic diseases, basal insulin peglispro, medicine.disease, Hypoglycemia, Diabetes Mellitus, Type 1, Basal (medicine), Diabetes Mellitus, Type 2, business, hypoglycaemia |
| الوصف: | Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, including three double-blind trials. Prespecified pooled analyses (n = 4927) included: patients with type 2 diabetes (T2D) receiving basal insulin only, those with T2D on basal-bolus therapy, and those with type 1 diabetes (T1D). BIL treatment resulted in a 36-45% lower nocturnal hypoglycaemia rate compared with glargine, despite greater reduction in glycated haemoglobin (HbA1c) and higher basal insulin dosing. The total hypoglycaemia rate was similar in patients with T2D on basal treatment only, trended towards being higher (10%) in patients with T2D on basal-bolus treatment (p = .053), and was 15% higher (p < .001) with BIL versus glargine in patients with T1D, with more daytime hypoglycaemia in the T1D and T2D groups who were receiving basal-bolus therapy. In T1D, during the maintenance treatment period (26-52 weeks), the total hypoglycaemia rate was not significantly different. There were no differences in severe hypoglycaemia in the T1D or T2D pooled analyses. BIL versus glargine treatment resulted in greater HbA1c reduction with less nocturnal hypoglycaemia in all patient populations, higher daytime hypoglycaemia with basal-bolus therapy in the T1D and T2D groups, and an associated increase in total hypoglycaemia in the patients with T1D. |
| اللغة: | English |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf2d286b1cb0a0d028876a7eb402840Test http://europepmc.org/articles/PMC5096011Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....adf2d286b1cb0a0d028876a7eb402840 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|